CharlieAJA/iStock through Getty Images
Announcing financials for 2022, animal well being firm Zomedica (NYSE:ZOM) mentioned Wednesday that its income for the total yr jumped ~361% to $18.9M via a mixture of acquisitions and natural development.
Revenue development was pushed by the primary full yr of PulseVet gross sales following the 2021 acquisition and not too long ago acquired Assisi merchandise. However, Zomedica’s (ZOM) income rose solely 25% when adjusted for pre-acquisition gross sales of PulseVet and Assisi merchandise.
As PulseVet gross sales grew 23% to $4.9M, income for This fall 2022 rose 51% YoY to $6.2M, whereas gross margin reached 70%, a decline from 72% for the total yr, which in flip dropped from 74% in 2021.
Zomedica’s (ZOM) money burn stood at $2.5M within the ultimate quarter, and the corporate’s money, money equivalents, and available-for-sale securities reached $156M on the finish of the yr, indicating a ~20% decline primarily as a consequence of money flows utilized in working and investing actions.
“Our Assisi Loop® line of products, which joined Zomedica’s portfolio of offerings in Q3, proved to be a solid contributor to our 2022 results with roughly $2.1M in sales for the year,” Chief Executive Larry Heaton remarked.
Read: In January, Seeking Alpha contributor Out of Ignorance argued that Zomedica’s (ZOM) “buy and build strategy is highly appealing.”
